XNCR stock sentiment todayXencor, Inc.
Sentiment verdict
Gossip first, financials second — NEUTRAL at 75% confidence.
Last updated · cached analysis, refreshes periodically
XNCR
Xencor, Inc.A clinically validated platform play with a fortress balance sheet, currently transitioning from early-stage R&D to high-stakes late-stage oncology readouts.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for XNCR. Not financial advice.
Price · last 12 months
Gossip
Recent market chatter focuses on Xencor's pivot toward B7-H3 and CD28 bispecific antibodies. Investors are encouraged by the high volume of 'smart money' institutional ownership and the company's ability to ink lucrative licensing deals with Big Pharma, which validates their XmAb technology.
- ·Optimism surrounding vudalimab monotherapy data
- ·Speculation on XPro platform's potential in neuroinflammation
- ·Partnership validation from heavyweights like Amgen and Genentech
Financial
Xencor boasts a robust cash runway extending into 2027, a rarity in the biotech sector. While currently unprofitable due to heavy R&D spend, their high-margin royalty streams from approved products like Monjuvi provide a safety net that most peers lack.
- ·Cash and equivalents of ~$600M+
- ·Zero long-term debt
- ·Multiple revenue-generating licensed products (Monjuvi, Ultomiris)
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Mixed conviction — no decisive signal from insiders or the holder base.
- ·No open-market insider trades in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·High clinical trial failure risk for bispecific candidates
- ·Heavy reliance on partner execution for royalty growth
- ·Increasing competition in the CD3 and CD28 oncology space
Peer temperature
How direct competitors stack up against XNCR right now.
- HOTZLABZai Lab Limited
HOTTER — faster commercial ramp-up and more diversified portfolio of approved late-stage oncology assets in the China market.
See full analysis → - COLDADAPAdaptimmune Therapeutics
COLDER — much thinner cash runway and higher volatility despite recent FDA accelerated approval for Tecelra.
See full analysis → - NEUTRALMRSNMersana Therapeutics
NEUTRAL — similar platform-based approach but facing more significant clinical setbacks in their ADC pipeline compared to Xencor's stable XmAb platform.
See full analysis →
- XNCR+19.5%
- ZLAB-16.2%
- ADAP—
- MRSN—
Analyst price target
Consensus average of 10 analysts · median 44.00
Source: StockAnalysis.com · updated 2026-10-27
AI-generated analysis for informational purposes only. Not financial advice.